Markets:

Overview

News

Currencies

International

Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

11.13 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

April 02, 2024

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 02, 2024

Via Benzinga

Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol ↗

April 02, 2024

Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with...

Via Benzinga

Verve Therapeutics: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

Why Verve Therapeutics Stock Crashed as Much as 30% This Week ↗

November 17, 2023

There was a concerning development in the company's clinical trials.

Via The Motley Fool

Crude Oil Surges Over 1%; US Factory Orders Increase In February ↗

April 02, 2024

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 while the NASDAQ fell 1.17% to 16,205.37. The S&P 500...

Via Benzinga

Topics Stocks

Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects ↗

April 02, 2024

The company is now pausing enrollment in the study of its lead asset, VERVE-101.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 02, 2024

Via Benzinga

3 Stocks That Could Be the Next Big Thing in Gene Editing ↗

March 21, 2024

Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.

Via InvestorPlace

Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗

February 27, 2024

Both companies are working on treatments for genetic disorders.

Via Investor's Business Daily

After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy? ↗

November 16, 2023

It reported some very bad news, but the market might be overreacting.

Via The Motley Fool

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential ↗

February 19, 2024

Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.

Via InvestorPlace

3 Gene Editing Stocks With Unprecedented Surge Potential ↗

February 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

Via InvestorPlace

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare ↗

February 12, 2024

It's less scary to take on risky investments when the market is rising.

Via The Motley Fool

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential ↗

January 31, 2024

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example.

Via InvestorPlace

Why Beam Therapeutics Stock Zoomed 17% Higher Today ↗

January 29, 2024

JPMorgan Chase becomes the latest institution in the company's bull pen.

Via The Motley Fool

7 Mighty Healthcare Stocks Changing the Game of Medicine ↗

January 17, 2024

Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks.

Via InvestorPlace

3 Stocks to Buy in the Booming Field of Gene Editing ↗

January 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

Via InvestorPlace

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics ↗

December 31, 2023

Curing rare inherited illnesses could be a lucrative business model.

Via The Motley Fool

$18M Bet On Verve Therapeutics? Check Out These 3 Stocks Insiders Are Buying ↗

December 06, 2023

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

Via Benzinga

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

November 29, 2023

Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS...

Via Benzinga

Why Verve Therapeutics Stock (VERV) Is Falling ↗

November 29, 2023

Verve Therapeutics Inc (NASDAQ: VERV) shares are trading lower by 6.3% to $11.18 Wednesday morning after the company priced its proposed public offering of common stock and

Via Benzinga

Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

November 29, 2023

Shares of Workday, Inc. (NASDAQ: WDAY) surged in pre-market trading after the company reported upbeat earnings results for its third quarter.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 29, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 29, 2023

Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning!

Via InvestorPlace

Leslie's Posts Weak Earnings, Joins Las Vegas Sands, Verve Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 29, 2023

U.S. stock futures traded higher this morning, with the Dow Jones futures gaining around 100 points on Wednesday.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 28, 2023

Via Benzinga

Verve Therapeutics: Why Great Results Aren't Enough ↗

November 16, 2023

The company's twist on CRISPR appears to work as intended but that didn't stop this biotech's stock price from collapsing.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

Headline News about Verve Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today